Navigation Links
Oncothyreon announces closing of $11.1 million registered direct financing
Date:5/27/2009

SEATTLE, May 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) announced today that it closed its previously announced sale of 3,878,993 shares of its common stock and warrants to purchase 2,909,244 shares of its common stock for gross proceeds of approximately $11.1 million on May 26, 2009. Oncothyreon sold the shares and warrants for $2.85 per unit (each unit consisting of one share and a warrant to purchase 0.75 shares of common stock). The exercise price of the warrants is $3.92 per share. The warrants will be exercisable at any time on or after the six-month anniversary and on or prior to the fifth anniversary of the closing of the transaction on May 26, 2009. Oncothyreon plans to use the proceeds from this financing for general corporate purposes. Boenning & Scattergood, Inc. acted as exclusive placement agent in the transaction.

A registration statement relating to these securities (File # 333-149837) has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor, shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration statement and any prospectus supplement that may be issued with respect to such offering. Copies of the final prospectus, including the prospectus supplement, can be obtained at the Securities and Exchange Commission's website, www.sec.gov, from Oncothyreon at its Seattle, Washington address below or Boenning & Scattergood, Inc. by calling 1-800-883-1212.

About Oncothyreon

<
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
2. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
3. Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
4. Oncothyreon reports first quarter 2009 financial results
5. Oncothyreon regains compliance with NASDAQ listing requirements
6. Oncothyreon to present at Invest Northwest 2009
7. Oncothyreon reports full year and fourth quarter 2008 financial results
8. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
9. Oncothyreon to present at BIO CEO & Investor Conference 2009
10. Oncothyreon reports third quarter 2008 financial results
11. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Decision Resources Group finds that the majority ... the United States believe that ... be the level of savings achievable by their ... cost to patients. Payers plan to leverage preferential ... expectations in order to encourage physician prescribing of ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
(Date:7/30/2014)... Chicago Bears are excited to announce the team,s partnership ... effort to raise awareness of skin cancer. Through this ... skin cancer screenings at a preseason fan event on ... me™ is an educational campaign designed to inform the public, ... cancer, and encourages people to get screened by a ...
(Date:7/30/2014)... LONDON , July 30, 2014  Replikins Ltd. ... structure of the Ebola virus. Before the current outbreaks, ... Replikins per 100 amino acids) between 1995 and 2002 ... 2010, threefold in 2012, and sixteen-fold in 2013, thus ... the past, this technology has been shown to be ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... such tests on samples sent in from all over Spain. ... truly personalised medicine. And researchers are exploring new ways to ... scale: the genes that are being read or transcribed; the ... the length of the telomeres capping its chromosomes. The ...
... or ultracapacitors, differ from regular capacitors that you would ... store substantially higher amounts of charges. They have garnered ... discharge faster than batteries, yet they are still limited ... energy density of batteries. An EC that combines the ...
... March 16, 2012  Tarsa Therapeutics, Inc. today announced ... financing led by new investor Foresite Capital.  James ... Tarsa,s Board of Directors.  Tarsa,s existing venture capital ... Partners—all participated in the new financing round.  ...
Cached Biology Technology:CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3Researchers develop graphene supercapacitor holding promise for portable electronics 2Researchers develop graphene supercapacitor holding promise for portable electronics 3Researchers develop graphene supercapacitor holding promise for portable electronics 4Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 3Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 4
(Date:7/30/2014)... study of dominance in female baboons suggests that the route ... mom, and to have lots of supportive sisters. , A ... strength, but by the rank of her mother - the ... be. For this reason, dominance rank in female baboons is ... mothers are guaranteed a good spot in the pecking order, ...
(Date:7/30/2014)... The Jackson Laboratory has received a pledge of $1 ... and name the Laboratory,s new Neurobehavioral Biometry Center. ... Biometry Center will enable the Laboratory to develop a ... with the ultimate goal of accelerating the pace of ... will serve as a premier resource for the Laboratory ...
(Date:7/30/2014)... Clemson University associate professor Andrew S. Mount, performed cutting-edge ... way for novel anti-fouling paint for ships and boats ... , The team,s findings, published in Nature ... barnacles that attaches to a wide variety of surfaces ... as an underwater heavy-duty adhesive. , "In previous research, ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... project to teach undergraduate students about network analysis, turned ... to analyze a National Basketball Association (NBA) basketball team,s ... discovered it is possible to quantify both a team,s ... in an online November issue of PLOS ONE ...
... research from Georgia Aquarium and Georgia Institute of Technology ... can be used to determine the health status of ... fish species. The study, led by Dr. Alistair Dove, ... an adjunct professor at Georgia Tech, found that the ...
... Robertson (Rob) McClung is not your typical clock-watcher. His ... based on a 24-hour period. Living organisms depend upon ... rotation and the recurring changes it imposes on the ... anticipate the changes and adapt to them by modifying ...
Cached Biology News:Basketball teams offer insights into building strategic networks 2New whale shark study used metabolomics to help understand shark and ray health 2Dartmouth research: The clocks are ticking and the climate is changing 2Dartmouth research: The clocks are ticking and the climate is changing 3Dartmouth research: The clocks are ticking and the climate is changing 4
... causing shortages in your laboratory or fellow ... cause unwanted distractions, problems and delays. • ... hard work and endeavour! Bring us your ... and market it internationally. We work under ...
... Perhaps sheer in-house demand is causing shortages ... precious antibody. This can cause unwanted distractions, ... Receive royalties for your hard work ... let us build it up,and market it ...
Topoisomerase I...
...
Biology Products: